In the last trading session, 1.01 million shares of the Edgewise Therapeutics Inc (NASDAQ:EWTX) were traded, and its beta was 0.27. Most recently the company’s share price was $22.80, and it changed around -$0.57 or -2.44% from the last close, which brings the market valuation of the company to $2.17B. EWTX currently trades at a discount to its 52-week high of $38.12, offering almost -67.19% off that amount. The share price’s 52-week low was $14.90, which indicates that the current value has risen by an impressive 34.65% since then. We note from Edgewise Therapeutics Inc’s average daily trading volume that its 10-day average is 1.7 million shares, with the 3-month average coming to 1.14 million.
Edgewise Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.22. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 1 recommended EWTX as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Edgewise Therapeutics Inc is expected to report earnings per share of -0.42 for the current quarter.
Edgewise Therapeutics Inc (NASDAQ:EWTX) trade information
Instantly EWTX has showed a red trend with a performance of -2.44% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 27.07 on recent trading dayincreased the stock’s daily price by 15.77%. The company’s shares are currently down -14.61% year-to-date, but still down -14.06% over the last five days. On the other hand, Edgewise Therapeutics Inc (NASDAQ:EWTX) is -8.84% down in the 30-day period. We can see from the shorts that 8.73 million shares have been sold at a short interest cover period of 8.97 day(s).
The consensus price target as assigned by Wall Street analysts is $50, which translates to bulls needing to increase their stock price by 54.4% from its current value. Analyst projections state that EWTX is forecast to be at a low of $50 and a high of $51.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -49.00%. Edgewise Therapeutics Inc earnings are expected to increase by -31.66% in 2025, but the outlook is negative -13.50% per year for the next five years.
EWTX Dividends
Edgewise Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Mar-02.
Edgewise Therapeutics Inc (NASDAQ:EWTX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.46% of Edgewise Therapeutics Inc shares, and 111.04% of them are in the hands of institutional investors. The stock currently has a share float of 111.56%. Edgewise Therapeutics Inc stock is held by 278.0 institutions, with ORBIMED ADVISORS LLC being the largest institutional investor. By 2024-06-30, it held 16.0634% of the shares, which is about 15.02 million shares worth $270.54 million.
RA CAPITAL MANAGEMENT, L.P., with 9.5269% or 8.91 million shares worth $160.45 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 2.52 shares worth $57.43 million, making up 2.65% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 1.96 shares worth around $44.77 million, which represents about 2.06% of the total shares outstanding.
